|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Fascin-1 and MAP17 are stem cell markers whose excessive expression in tumors is associated with aggressive tumor phenotypes.
|
31273628 |
2019 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Expression of fascin-1 and MAP17 was assessed via immunohistochemistry in surgical specimens of a cohort comprised of 127 patients with resectable breast cancer.
|
31273628 |
2019 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Expression of fascin-1 and MAP17 was assessed via immunohistochemistry in surgical specimens of a cohort comprised of 127 patients with resectable breast cancer.
|
31273628 |
2019 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
In a xenograft tumor model in which TGF-β was previously shown to elicit tumor-promoting effects, PDZK1IP1 gain of function decreased tumor size and increased survival rates.
|
30718277 |
2019 |
|
Carcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
MAP17 (PDZK1IP1) is a small, 17 kDa non-glycosylated membrane protein located in the plasma membrane and Golgi apparatus and is overexpressed in a wide variety of human carcinomas.
|
30250642 |
2018 |
|
Rectal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In the present manuscript, we examined the values of MAP17 and pH2AX as surrogate biomarkers of the response in rectal tumors.
|
30250642 |
2018 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
We show that MAP17 expression is induced during lung tumourigenesis, particularly in lung adenocarcinomas, and provide in vitro and in vivo evidence that MAP17 levels predict sensitivity to therapies currently under clinical use in adenocarcinoma tumours, including cisplatin, carboplatin and EGFR inhibitors.
|
30119639 |
2018 |
|
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, MAP17 is correlated with tumour progression.
|
30119639 |
2018 |
|
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We show that MAP17 expression is induced during lung tumourigenesis, particularly in lung adenocarcinomas, and provide in vitro and in vivo evidence that MAP17 levels predict sensitivity to therapies currently under clinical use in adenocarcinoma tumours, including cisplatin, carboplatin and EGFR inhibitors.
|
30119639 |
2018 |
|
Lung Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results indicate a potential prognostic role for MAP17 in lung tumours, with particular relevance in lung adenocarcinomas, and highlight the predictive pot0065ntial of this membrane-associated protein for platinum-based therapy and EGFR inhibitor efficacy.
|
30119639 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, we show that MAP17 expression predicts proteasome inhibitor efficacy in this context and that bortezomib, an FDA-approved drug, may be a novel therapeutic approach for MAP17-overexpressing lung adenocarcinomas.
|
30119639 |
2018 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
MAP17 is aberrantly overexpressed in a number of malignancies.
|
29616128 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.
|
29616128 |
2018 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively these findings suggest that MAP17 serves a role in TKI resistance through regulation of CSCs in lung cancer.
|
29616128 |
2018 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively these findings suggest that MAP17 serves a role in TKI resistance through regulation of CSCs in lung cancer.
|
29616128 |
2018 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively these findings suggest that MAP17 serves a role in TKI resistance through regulation of CSCs in lung cancer.
|
29616128 |
2018 |
|
Psoriasis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry confirms local inflammation, mainly CD45<sup>+</sup> cells, at the site of expression of MAP17, at least in tumors, Crohn's and psoriasis.
|
29228712 |
2017 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
High MAP17 expression was positively correlated with gender, distant metastasis, early recurrence (≤ 2 year), and serum alpha-fetoprotein (all <i>p</i> < 0.05).
|
29190940 |
2017 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cox regression analysis indicated MAP17 was an independent prognostic factor for DFS (HR, 1.710; 95% CI, 1.156-2.449, <i>p</i> = 0.012) and OS (HR, 1.743; 95% CI, 1.152-2.639, <i>p</i> = 0.009) in HCC.
|
29190940 |
2017 |
|
Atrial Fibrillation
|
0.010 |
Biomarker
|
disease |
BEFREE |
Paroxysmal AF comparing to permanent AF and SR individuals had higher estimated SPAP (56 versus 48 versus 47 mmHg, <i>p</i> = 0.01) and shorter ACT (58 versus 65 versus 70 ms, <i>p</i> = 0.04).
|
28280732 |
2017 |
|
Idiopathic pulmonary arterial hypertension
|
0.010 |
Biomarker
|
disease |
BEFREE |
(1) Compared with the control group, the PAH group had lower body mass and weight increment, and relative to the latter, 5-ASA-treated groups had larger body mass and weight increment except for groups 5-ASA-150 and 5-ASA-200 and greater overall survival rates; (2) SPAP, DPAP, MPAP, and RVHI in 5-ASA-treated groups, except for MPAP and RVHI in 5-ASA-200 group, were lower than those in the PAH group; (3) compared with the PAH group, Nur77 expression in the pulmonary arteries of 5-ASA-treated groups was increased; and (4) expression of inflammatory mediators (NF-κB p65) was lower, while that of IκBα was higher in the pulmonary arteries of 5-ASA-treated groups and control group than that in the PAH group (all P < 0.05).
|
28213866 |
2017 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Conversely, MAP17 downregulation in a tumor cell line constitutively expressing this gene led to Notch pathway inactivation and a marked reduction of stemness.
|
28153862 |
2017 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB.
|
28153862 |
2017 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB.
|
28153862 |
2017 |
|
Intrahepatic Cholangiocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Differential gene expression analysis demonstrated significant upregulation of PDZK1IP1, EEF1A2 and RPL41 (ENSG00000279483) genes in the iCCA samples when compared with the matched para‑tumor samples.
|
27082702 |
2016 |